

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

GILEAD SCIENCES, INC.

Plaintiff,

v.

APOTEX, INC., LUPIN LIMITED, LAURUS LABS LIMITED, SHILPA MEDICARE LIMITED, SUNSHINE LAKE PHARMA CO., LTD., NATCO PHARMA LIMITED, CIPLA LIMITED, MACLEODS PHARMACEUTICALS LTD., HETERO USA INC., HETERO LABS LIMITED UNIT-V AND HETERO LABS LIMITED,

Defendants.

C.A. No. 20-cv-00189-MN

**CONSENT JUDGMENT AND ORDER**

This action for patent infringement having been brought by Plaintiff Gilead Sciences, Inc. (“Gilead”) against defendant Macleods Pharmaceuticals Ltd. (“Macleods”) for infringement of U.S. Patent Nos. 8,754,065; and 9,296,769.

Gilead and Macleods (“the Parties”) have agreed to the terms and conditions in a confidential Settlement and License Agreement (the “Agreement”) and accordingly, have agreed to terminate the pending litigation by the entry of this Judgment and Order; and

The Parties now consent to this Judgment and Order.

IT IS HEREBY ORDERED, ADJUDGED AND DECREED:

1. This Court has jurisdiction over the Parties and subject matter of this action.
2. All affirmative defenses, claims and counterclaims, which have been or could have been raised with respect to Macleods ANDA by Gilead against Macleods and its Affiliates, or by

Macleods and its Affiliates against Gilead, in this action are hereby dismissed without prejudice. For purposes of this Judgment and Order, “Affiliates” means any entity controlling, controlled by, or under common control with Macleods, but only as long as such control continues, where “control” and its correlates means (a) the ownership of at least fifty percent (50%) of the equity or beneficial interest of such entity, (b) the right to vote for or appoint a majority of the board of directors or other governing body of such entity, or (c) the power, whether pursuant to contract, ownership of securities, or otherwise, to direct the management and policies of such entity.

3. Except as otherwise provided by the Parties’ Agreement, Macleods and its Affiliates are hereby enjoined from making, having made, using, having used, offering for sale, having offered for sale, selling, or having sold in the United States, or importing or having imported into the United States, the products of ANDA No. 214216 (the “Macleods ANDA”) until permitted under the Parties’ Agreement.

4. The Parties waive all right to appeal from this Judgment and Order.

5. This Court shall retain jurisdiction of this action and over the parties for purposes of enforcement of the provisions of this Judgment and Order.

6. As provided in the Agreement, Parties are permitted to notify FDA in writing of the relevant terms of the Agreement.

7. Each Party is to bear its own costs and attorneys’ fees.

Dated: September 9, 2022

/s/ Grayson P. Sundermeir

Douglas E. McCann (#3852)  
Grayson P. Sundermeir (#6517)  
Fish & Richardson P.C.  
222 Delaware Avenue, 17th Floor  
(302) 6521-5070  
Wilmington, DE 19801  
dmccann@fr.com;  
sundermeir@fr.com

*Attorneys for Plaintiff  
Gilead Sciences, Inc.*

/s/ John M. Seaman

John M. Seaman (#3868)  
April M. Ferraro (#6152)  
ABRAMS & BAYLISS LLP  
20 Montchanin Road, Suite 200  
Wilmington, DE 19807  
(302) 778-1000 phone  
seaman@abramsbayliss.com  
ferraro@abramsbayliss.com

*Attorneys for Defendant  
MacLeods Pharmaceuticals Ltd.*

**IT IS SO ORDERED** this \_\_\_\_\_ day of \_\_\_\_\_ 2022.

The Honorable Maryellen Noreika  
United States District Judge